144 related articles for article (PubMed ID: 10527071)
1. Short-term cultures of clinical tumor material: potential contributions to oncology research.
Baguley BC; Marshall ES; Finlay GJ
Oncol Res; 1999; 11(3):115-24. PubMed ID: 10527071
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
3. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
4. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
Prestwich GD
Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
[TBL] [Abstract][Full Text] [Related]
5. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
[TBL] [Abstract][Full Text] [Related]
7. Antitumor interaction of short-course endostatin and ionizing radiation.
Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
[TBL] [Abstract][Full Text] [Related]
8. A sensitive assay for the evaluation of cytotoxicity and its pharmacologic modulation in human solid tumor-derived cell lines exposed to cancer-therapeutic agents.
Mirzayans R; Andrais B; Scott A; Tessier A; Murray D
J Pharm Pharm Sci; 2007; 10(2):298s-311s. PubMed ID: 17718933
[TBL] [Abstract][Full Text] [Related]
9. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
Gerçel-Taylor C; Ackermann MA; Taylor DD
Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
[TBL] [Abstract][Full Text] [Related]
11. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
13. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
Ng TY; Ngan HY; Cheng DK; Wong LC
Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
[TBL] [Abstract][Full Text] [Related]
14. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
Ness RB; Wisniewski SR; Eng H; Christopherson W
Anticancer Res; 2002; 22(2B):1145-9. PubMed ID: 12168915
[TBL] [Abstract][Full Text] [Related]
15. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
[TBL] [Abstract][Full Text] [Related]
18. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.
Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT
J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.
Bosanquet AG; Bell PB
J Exp Ther Oncol; 2004 Jul; 4(2):145-54. PubMed ID: 15500009
[TBL] [Abstract][Full Text] [Related]
20. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]